Background: Peripheral T-cell lymphomas (PTCL) account for about 10% of all lymphomas in Western countries. The aim of the present study is to analyze the initial characteristics and prognostic factors in a large series of PTCL patients.
Introduction
Peripheral T-cell lymphomas (PTCL) are neoplasias derived from post-thymic lymphoid T cells at different steps of differentiation [1, 2] . PTCL are rare in Western countries, where they constitute about 10% of all lymphoid tumors [3] [4] [5] [6] [7] . Such a proportion increases to 70%-80% in Japan and other Eastern areas for epidemiological reasons, including the HTLV-1 infection [8] [9] [10] . Until recently the distinction between B-cell-and T-cell-origin lymphomas had not been extensively applied to the classification of lymphoma. During the past decade, the extensive use of immunohistochemestry, in addition to molecular biology techniques, has allowed the correct diagnosis of T-cell neoplasms. Although often considered as one group, PTCL are actually very heterogeneous, and a wide variety of different categories have been recognized [1, 2, [11] [12] [13] [14] [15] [16] [17] [18] [19] . Some of these entities are well defined from the biological and clinical points of view (e.g., anaplastic large-cell lymphoma or angioimmunoblastic lymphoma), but most of them need further investigation.
From the clinical standpoint, along with cutaneous lymphomas, PTCL have been considered aggressive diseases. In this sense, the prognostic significance of immunophenotype in aggressive lymphomas has been extensively analyzed [4, 5, [20] [21] [22] [23] [24] [25] . Although no significant differences were found between B-cell and T-cell lymphomas in some studies [20, 23, 25] , most analyses concluded that PTCL patients have poorer prognoses in terms of response to therapy and survival [4, 5, 21, 22, 24] . However, PTCL are a heterogeneous group of neoplasias whose aggressiveness may vary depending on subtype. There are actually data indicating distinctive prognostic features for each subgroup [7] . On the other hand, whereas the number of studies on prognostic factors in aggressive lymphomas is large [26] [27] [28] , in only a few of them have PTCL patients been specifically analyzed. Finally, the usefulness of the International Prognostic Index [29] (IPI), built up for aggressive lymphomas without phenotype distinction, has not been completely tested in PTCL. Because of the low number of cases in each institution, cooperative studies are needed to answer these questions.
The main goals of the present study were to analyze the initial characteristics of a large series of patients diagnosed with PTCL in nine institutions, according to the different histologic subtypes, to assess the response to therapy and survival, and to analyze the most important prognostic factors. Although consecutive cases were chosen for the study, those patients with no material for immunophenotyping studies necessary for the diagnosis of PTCL were excluded. Cutaneous T-cell lymphoma, T-cell chronic lymphocytic leukemia/ prolymphocytic leukemia, adult T-cell leukemia/lymphoma and large granular lymphocyte leukemia were excluded from the analysis. Some of the patients had been recorded and reported in a previous paper [30] .
Patients and methods

Patients
The main pre-treatment characteristics of the patients are detailed in the Results section. The median follow-up for surviving patients was 26 months.
eral T-cell lymphoma unspecified, 95 cases (54.4%), ALCL, 30 cases (17%); angioimmunoblastic T-cell lymphoma (AILD), 22 cases (13%); angiocentric lymphoma, 14 cases (8%); intestinal T-cell lymphoma, 12 cases (7%); and hepatosplenic y8 T-cell lymphoma, one case (0.6%).
Parameters evaluated
In each patient the following parameters were recorded and evaluated for prognosis: 1) Histological subtype: according to the R.E.A.L. Classification; 2) Clinical information: age, sex, performance status (according to the Eastern Cooperative Oncology Group (ECOG) scale), and presence of B-symptoms (fever, night sweats, weight loss); 3) Hematological and laboratory parameters: Hb,WBC count, lymphocyte count, presence of atypical lymphocytes in peripheral blood, platelet count, total serum proteins, serum albumin, serum LDH levels, and serum p2-microglobulin (B2M) levels; 4) Tumor extension data: number of nodal and extranodal involved sites, hepatomegaly, splenomegaly (in cm below costal margin in both cases), Ann Arbor stage, presence of bulky disease (defined as the presence of a bulky mass with a diameter > 10 cm), and bone marrow infiltration; and 5) International Prognostic Index (IPI) for Aggressive Lymphomas: as described by the International Non-Hodgkin's Lymphoma Prognostic Project [28] .
Complete response (CR) was defined as the disappearance of all signs and symptoms of disease as determined by clinical, radiographic, and laboratory parameters, including a bone marrow biopsy if positive at diagnosis. Patients who responded to therapy and had residual radiographic abnormalities (less than 20% of the original mass) that remained unchanged for more than six months after treatment was discontinued were considered to be in CRu. Partial response (PR) was defined as a reduction of 50% or more in measurable disease for at least one month. Any other response, including mixed response, stable disease, progressive disease, early death, or death from toxicity were considered as treatment failures.
Statistical methods
End-points of the study were response to therapy, duration of response and survival. The univariate analysis was performed for each of the parameters indicated above. The actuarial survival analysis was performed according to the method described by Kaplan and Meier [31] , and the curves compared by the log-rank test [32] . All significant prognostic variables in the univariate analysis, with the exception of serum B2M that was available for only 48 patients, were considered for the multivariate analysis for survival. The latter was performed by Cox's stepwise proportional hazard regression method [33] .
Results
Histopathologic criteria
Patients were diagnosed according to the criteria established by the International Lymphoma Study Group in the R.E.A.L. Classification [2] . All of the samples were diagnosed by members of the Spanish Lymphoma Study Group (Club Espafiol de Linfomas), according to uniform pathologic criteria. In all cases a basic panel of monoclonal antibodies was used on either paraffin or frozen sections, including CD2, CD3, CD5, CD7, CD4 and CD8. In addition, CD20 and CD79a were used in order to rule out a B-cell origin of the neoplastic cells. Cytogenetic and molecular techniques, including T-cell receptor and NPM/ALK rearrangement analyses, were available only in a minority of the cases. Regarding anaplastic large-cell Ki-1 lymphoma (ALCL) subtype, only T cell and 'null'-ALCL were included as PTCL according to the R.E.A.L. Classification. B-cell ALCLs were considered B-cell large-cell lymphomas and, subsequently, excluded from the present study. Primary cutaneous ALCLs were also excluded from the study.
The histologic distribution, according to the classification of the International Lymphoma Study Group [2] , was the following: periph-
Pre-treatment characteristics of the patients
The main pre-treatment characteristics of the patients according to the histologic subtype are detailed in Table 1 . Although the median age of the series as a whole was 61 years (range 14-87), ALCL and angiocentric PTCL patients tended to be younger, with a median of age of 46 and 38 years, respectively. ALCL patients constituted a particular group of PTCL cases, with favorable prognostic features compared to the remaining PTCL: 93% were in ambulatory performance status (ECOG <2, vs. 32% in other subtypes; P -0.005), 50% had no extranodal involvement (vs. 31%; P -0.06), 50% were in early Ann Arbor stages (I or II, vs. 18%; P < 0.001), and 90% presented with normal serum B2M levels (vs. 34%; P < 0.01). No significant differences were found between ALCL and the other PTCL according to the presence of bulky disease, bone marrow infiltration, and serum LDH levels.
The most frequently involved extranodal sites are listed in Table 2 . Noteworthy is the relatively high incidence of skin infiltration in the majority of PTCL subtypes. Angiocentric PTCL presented with ORL area and CNS infiltration in 50% and 21% of the cases, respectively. Intestinal T-cell lymphomas showed no extranodal infiltration other than intestinal, with the exception of bone marrow in one case.
We applied the IPI to PTCL patients (Table 1 ). There were significant differences according to that index between ALCL (61% of patients were of low-risk) and the remaining PTCL (22 to 30% were of low-risk; P < 0.01 vs. ALCL).
Treatment and response to therapy
Since this was not a prospective study, patients were not treated homogeneously. One hundred fifty-five patients (89%) received adriamycin-containing regimens (120 patients standard CHOP, 35 patients either second (w = 5) or third generation (« = 30) chemotherapies), and 12 patients (7%) no adriamycin-containing regimens. In seven cases (4%) only palliative treatment was administered due to either poor performance status or advanced age of the patients. The latter cases were not included in the evaluation of response to therapy. No differences were observed among the different histologic subgroups according to the therapy given to the patients.
Response to therapy was assessable in 163 of the 174 cases (seven patients receiving palliative treatment, and four patients lost to follow up were excluded). Seventynine patients (49%) achieved CR, 25 (15%) PR, and 59 (36%) were refractory to initial therapy. Response to therapy among the different histologic subgroups is shown in Table 3 . Interestingly, ALCL patients more frequently achieved CR than the remaining PTCL (69% vs. 45%, P < 0.02). No significant differences were found among the other subgroups. Of note, however, is that only three out of 12 (27%) intestinal T-cell patients achieved CR.
In the univariate analysis, the following parameters predicted CR achievement: ALCL subtype (P < 0.02), age < 65 years (P < 0.05), ambulatory performance status (ECOG < 2; P < 0.03), absence of B-symptoms (P < 0.01), no extranodal involvement (P < 0.001), no bone marrow infiltration (P < 0.01), Ann Arbor stage I or II (P < 0.001), normal platelet count (P < 0.025), normal serum LDH (P < 0.05) and B2M (P < 0.01) levels, and low-risk IPI (P < 0.001). No significant differences were found according to the treatment given to the patients (no adriamycin-containing regimens vs. CHOP vs. second/third generation chemotherapies).
In the overall series, 32 of the 79 patients in CR eventually relapsed. The median CR duration was 50 months, with a risk of relapse of 48% at four years after CR achievement (Figure 1) . No significant differences were found according to histologic subtype.
Survival
Eighty-nine patients had died at the time of the analysis. The survival curve of the series as a whole is plotted in Figure 2 . Median survival of the series was 22 months, with a four-year probability of survival of 38% (95% CI: 28-48).
Median survival for each histologic subtype is detailed in Table 3 . ALCL patients had a significantly longer survival than the other PTCL types (P -0.03, Figure 3 ). In the univariate analysis, the following variables were related to short survival in addition to histology: older age (^65 years; P < 0.005), poor performance status (ECOG ^2 ; P < 0.001), presence of B-symptoms (P -0.01), extranodal involvement (P -0.01), bone marrow infiltration (P < 0.025), advanced Ann Arbor stage (P < 0.005), high serum LDH (/> = 0.005) and high serum B2M (P -0.01) levels, and intermediate-/highrisk IPI (P < 0.001). The treatment administered to the patients (CHOP vs. second/third generation regimens) had no prognostic significance. A multivariate analysis was performed with the significant variables above indicated (serum B2M was not included, since it was available in only 48 cases). The histologic subgroup (ALCL vs. other PTCL) (P = 0.02; RR: 4.2; 95% CI: 1-18), the presence of B-symptoms (P = 0.02; RR: 2.2; 95% CI: 1.1-4.2), and the IPI (low + low/intermediate vs. high+high/inter-mediate risk) (P = 0.04; RR: 2; 95% CI: 1-3.9) were the most important variables for predicting survival.
PTCL unspecified
Prognostic factors were also analyzed in the subset of patients with unspecified PTCL that constituted the largest group of PTCL (95 patients; 55% of the whole series). The main pre-treatment characteristics, treatment, response to therapy and response duration have been previously listed (Tables 1, 2 and 3). Variables predicting for CR achievement were the following: age < 65 years (P < 0.05), absence of B-symptoms (P < 0.01), no extranodal involvement (P < 0.01), no bone marrow infiltration (P < 0.05), Ann Arbor stages I or II (P < 0.001), normal serum LDH (P < 0.01) and B2M (P = 0.05) levels, and low-risk according to the IPI (P < 0.001). No differences were found according to the treatment given to these patients.
Median survival of PTCL-unspecified patients was 22 months, with a four-year actuarial survival of 32% (95% CI: 21-43). The variables predicting poorer survival in the univariate analysis were: age ^65 years (P < 0.01), non-ambulatory performance status (ECOĜ 2, P < 0.002), presence of B-symptoms (P < 0.025), extranodal involvement (P < 0.05), bone marrow infiltration (P < 0.025), disseminated stage (P < 0.001, Figure 4 ), high serum LDH (P < 0.01), high serum B2M (P < 0.05), and high/intermediate-or high-risk IPI (P < 0.001, Figure 5 ). In the multivariate analysis only the IPI (low + low/intermediate vs. high/intermediate + high risk) maintained its independent value for predicting survival (P < 0.001; relative risk: 3.5; 95% CI: 1.7-7.1).
Discussion
The extensive use of immunophenotyping has made it possible to distinguish between B-cell and T-cell lymphomas in recent years. However, recognition of the different entities included as PTCLs in the R.E.A.L. Classification [2] is still difficult. In B-cell lymphomas the groups of this classification are defined by specific cytogenetic and/or molecular features that characterize these categories [2] . Otherwise, only a few PTCL have specific molecular alterations. The exception is the ALCL, which in most cases presents with the t(2;5) translocation that transcripts for a chimerical nucleophosmin/ anaplasic lymphoma kinase (NPM/ALK) product [34, 35]. Other entities, although showing particular characteristics at histologic study, are still under investigation. Anyway, as in B-cell lymphomas, under the term PTCL we include entities which are very heterogeneous from biological and clinical standpoints [2, 6, 36] .
Overall, the outcome of the patients with PTCL is basically unfavorable. Less than one-half reach CR and most of them eventually relapse, with a median survival of less than four years in most series [4, 5, [20] [21] [22] [23] [24] 37] . In this regard, our results basically agree with others previously reported. Moreover, no plateau can be observed in either the relapse or the survival curves: this indicates that the probability of cure is very rare in these patients. This has also been pointed out previously [5, 21, 37] . In the present analysis, the histology (ALCL vs. the other subtypes of PTCL), the presence of B-symptoms and the International Index were the most important variables for predicting response to therapy and survival. The prognostic role of the International Index, useful in all kinds of lymphomas, is interesting. However, the important point is whether or not by means of the International Index we are able to select a subset of patients who are likely to be cured with standard treatment. Although in the present series low-risk patients according to the International Index seem to have a plateau in the survival curve, this aspect should be confirmed: the number of patients at risk is too small to obtain conclusions. Recently, Ansell et al. [37] have shown similar results in their series: the International Index was the most important parameter predicting survival in PTCL, but there was no clear plateau in any of the subgroups. In fact, in other series, such as that from the French group GELA [24] and the one from M.D. Anderson Cancer Center [5] , low-risk patients, although with better prognoses than the others, do not have a real plateau in the survival curves.
The treatment given to the patients is an essential aspect that deserves comment. Most of our patients received adriamycin-containing chemotherapies, but only a minority of them were treated with second-or thirdgeneration regimens or other more intensive chemotherapies. Thus, the lack in the present series of significant differences among these treatments, in terms of CR rate and survival, should be considered with caution. The only clear conclusion is that CHOP is not a good therapy for PTCL patients with high, high/intermediate and low/intermediate risk, since less than 30% of them were alive at five years after diagnosis. The question iof whether more intensive treatments would be better than standard therapy in PTCL will be answered only by prospective studies. In fact, until recently, most prospective trials on aggressive lymphomas were carried out independently of the phenotype. Therefore, it is difficult to evaluate the role of intensive therapy, including peripheral or bone marrow stem cell transplantation, in PTCL.
Another question that has remained open for years is whether or not PTCL are more aggressive than B-cell large-cell lymphomas. In at least three studies [20, 23, 25] no differences were found in the outcome of the patients with aggressive lymphoma according to the phenotype. However, in other analyses [4, 5, 21, 22, 24] patients with PTCL showed poorer prognoses than B-cell lymphoma patients. The existence of such differences between T-cell and B-cell aggressive lymphomas has been recently confirmed in two different studies with large numbers of cases [5, 24] . Gisselbrecht et al. [24] in a GELA study observed that aggressive T-cell lymphomas had a CR rate of 54%, with a five-year freedom from progression of 33%, whereas the figures were 63% and 42%, respectively, for aggressive B-cell lymphomas. The group from M.D. Anderson Cancer Center (MDACC) [5] , using data from a single institution, concluded that PTCL patients presented with more unfavorable prognoses than B-cell patients. Moreover, they confirmed the unfavorable outcome of PTCL patients in the different groups of risk defined in the IPI [29] and the MDACC score [38] . In our analysis we were not able to assess this point, since it was not a controlled study.
ALCL constitutes, among PTCL, a particular goodprognosis group. ALCL patients have more favorable initial features, higher CR rates (69% in the present series), and longer survivals (median survival: 65 months in the present series) than the other subtypes of PTCL. Although the relapse rate was similar among ALCL patients and in other PTCL patients, both initial response and response to salvage treatment were higher in ALCLs. In fact, the behavior of these patients is closer to that of those with B-cell large-cell lymphomas than with other PTCL, which are, in general, much more aggressive. In this sense, our series confirms previously reported data [5, 15, 16] .
Among PTCL the unspecified group constitutes the most common subtype. The main conclusions for the whole series herein presented are also applicable to the unspecified subset: initial aggressiveness, low CR rate, high relapse rate, and poor survival. In the present study, the presence of B-symptoms and the International Index were the most important factors predicting response and survival in patients with PTCL unspecified. Although considered as a whole in the classification of the International Lymphoma Study Group, PTCL unspecified probably constitutes a heterogeneous group that may represent different subtypes of PTCL that currently we are not able to separate. The intent to divide PTCL unspecified has at least two important problems: the lack of reproducibility among pathologists and the lack of clinical and prognostic interest. Further studies are needed in order to complete the classification of PTCL unspecified.
In conclusion, PTCL have poor prognostic features at diagnosis, respond poorly to therapy and have short survivals, with no sustained remission. ALCL constitute a subgroup of PTCL with better response to treatment and survival. Histologic subtype (ALCL vs. other PTCL), the presence of B-symptoms and the International Prognostic Index were the most important variables predicting survival in PTCL. In the subset of PTCL unspecified the International Index was the most important prognostic factor for survival.
